File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis

TitleFibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis
Authors
KWOK, HMLam, KSL
KeywordsAtherosclerosis
Dyslipidemia
Fibroblast growth factor 21
Issue Date2017
PublisherKorean Endocrine Society. The Journal's web site is located at http://www.enm-kes.org/
Citation
Endocrinology and Metabolism, 2017, v. 32 n. 2, p. 145-151 How to Cite?
DOI: http://dx.doi.org/10.3803/EnM.2017.32.2.145
AbstractFibroblast growth factor 21 (FGF21) is an atypical member of the FGF family. Acting in an endocrine fashion, it increases glucose uptake, modulates lipid metabolism, and sensitizes insulin response in metabolically active organs, including the liver and adipose tissue. Emerging evidence shows a strong correlation between circulating FGF21 levels and the incidence and severity of atherosclerosis. Animal studies have demonstrated a beneficial role of FGF21 in protecting against aberrant lipid profile, while recent development in FGF21 mimetics has provided further insight into the lipid-lowering effects of FGF21 signaling. The present review summarizes the physiological roles of FGF21, and discusses major breakthroughs and limitations of FGF21 mimetic-based therapeutic strategies for treating atherosclerosis.
Persistent Identifierhttp://hdl.handle.net/10722/242226
ISSN
2093-596X
2021 Impact Factor: 3.607
2020 SCImago Journal Rankings: 0.906
ISI Accession Number ID
WOS:000407811300001

 

DC FieldValueLanguage
dc.contributor.authorKWOK, HM-
dc.contributor.authorLam, KSL-
dc.date.accessioned2017-07-24T01:36:59Z-
dc.date.available2017-07-24T01:36:59Z-
dc.date.issued2017-
dc.identifier.citationEndocrinology and Metabolism, 2017, v. 32 n. 2, p. 145-151-
dc.identifier.issn2093-596X-
dc.identifier.urihttp://hdl.handle.net/10722/242226-
dc.description.abstractFibroblast growth factor 21 (FGF21) is an atypical member of the FGF family. Acting in an endocrine fashion, it increases glucose uptake, modulates lipid metabolism, and sensitizes insulin response in metabolically active organs, including the liver and adipose tissue. Emerging evidence shows a strong correlation between circulating FGF21 levels and the incidence and severity of atherosclerosis. Animal studies have demonstrated a beneficial role of FGF21 in protecting against aberrant lipid profile, while recent development in FGF21 mimetics has provided further insight into the lipid-lowering effects of FGF21 signaling. The present review summarizes the physiological roles of FGF21, and discusses major breakthroughs and limitations of FGF21 mimetic-based therapeutic strategies for treating atherosclerosis.-
dc.languageeng-
dc.publisherKorean Endocrine Society. The Journal's web site is located at http://www.enm-kes.org/-
dc.relation.ispartofEndocrinology and Metabolism-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAtherosclerosis-
dc.subjectDyslipidemia-
dc.subjectFibroblast growth factor 21-
dc.titleFibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis-
dc.typeArticle-
dc.identifier.emailLam, KSL: ksllam@hku.hk-
dc.identifier.authorityLam, KSL=rp00343-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3803/EnM.2017.32.2.145-
dc.identifier.scopuseid_2-s2.0-85023204908-
dc.identifier.hkuros273618-
dc.identifier.volume32-
dc.identifier.issue2-
dc.identifier.spage145-
dc.identifier.epage151-
dc.identifier.isiWOS:000407811300001-
dc.publisher.placeRepublic of Korea-
dc.identifier.issnl2093-596X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats